S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.10
+360.20
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.23
+1.55
+9.29%
GMED · GLOBUS MEDICAL INC
NEW YORK STOCK EXCHANGE, INC. - BOATS Real Time Price • USD
Globus Medical Inc (GMED)
NEW YORK STOCK EXCHANGE, INC.
Health Care
$78.67
-0.31
(-0.39%)
● At close: October 21 at 4:00:00 PM EDT
$78.05
-0.63
(-0.80%)
Overnight:
8:30:43 PM EDT
DAY'S RANGE
$78.67
$77.97
$79.77
52-WEEK RANGE
$78.67
$59.51
$101.40
What's happening
- GMED is down 0.39% today, trading at $78.67. — Live quote
- Volume today (73,986) is well below its 3-month average of 1,592,560. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $1.34 actual vs. $1.12 estimated (+19.5%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 4
Buy 12
Hold 7
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (23 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
GMED
-9.56%
vs S&P 500
-22.34%
1-YEAR RETURN
GMED
+28.22%
vs S&P 500
+13.66%
6-MONTH RETURN
GMED
-14.88%
3-MONTH RETURN
GMED
+3.77%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$1.34
Est. $1.12
BEAT +19.5%
2026-04-26 (Q1 2026)
$1.12
Est. $0.94
BEAT +19.4%
2026-01-26 (Q4 2025)
$1.28
Est. $1.17
BEAT +9.2%
2025-10-26 (Q3 2025)
$1.18
Est. $0.80
BEAT +47.8%
Valuation Measures & Ratios
Enterprise Value4$10.09B
Forward P/E515.73
PEG Ratio60.40
Price / Sales (TTM1)3.37
Price / Book72.25
EV4 / Revenue3.21
EV4 / EBITDA13.18
Profit Margin17.03%
Operating Margin20.60%
Return on Equity (ROE8)11.59%
Return on Assets (ROA9)10.04%
Avg Volume (3M)1,592,560
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $10.89B | $11.90B | $7.75B | $8.03B | $10.23B |
| P/E | 18.22 | 22.81 | 17.26 | 22.20 | 67.31 |
| Price/Sales | 3.55 | 4.14 | 2.83 | 3.09 | 4.16 |
| Price/Book | 2.28 | 2.51 | 1.76 | 1.87 | 2.50 |
| EV/Revenue | 3.39 | 3.95 | 2.83 | 3.09 | 4.16 |
| EV/EBITDA | 12.54 | 15.35 | 12.24 | — | — |
| ROE | 12.53% | 11.02% | 10.21% | 8.42% | 3.72% |
| ROA | 10.89% | 9.59% | 8.81% | 7.29% | 3.23% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short8,437,114
Change from Prior Settlement+24.67%
% of Float—
Days to Cover (Short Ratio)5.14
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 5.9% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is 17.0%. Finnhub fundamentals ↗
- Trailing 52-week price return is +28.2%. Finnhub market metrics ↗
Potential concerns
- Latest SEC filing is Form 4, filed 2026-09-16; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on GMED
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $789.6M | $759.9M | $769.0M | $745.3M | $598.1M | $625.7M | $629.7M | $606.7M |
| Gross profit | — | — | — | — | — | — | $369.7M | $365.2M |
| Operating income | $182.4M | $150.4M | $137.4M | $76.1M | $97.0M | $48.1M | $49.6M | $8.0M |
| Net income | $151.6M | $124.3M | $119.0M | $202.8M | $75.5M | $51.8M | $31.8M | -$7.1M |
| EPS (diluted) | $1.10 | $0.90 | $0.88 | $1.49 | $0.54 | $0.38 | $0.23 | $-0.05 |
| EPS (basic) | $1.12 | $0.92 | $0.88 | $1.50 | $0.55 | $0.38 | $0.23 | $-0.05 |
| Operating margin | $23 | $20 | $18 | $10 | $16 | $8 | $8 | $1 |
| Net margin | $19 | $16 | $15 | $27 | $13 | $8 | $5 | -$1 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $5.49B | $5.44B | $5.30B | $5.10B | $4.96B | $4.71B | $5.25B | $5.09B |
| Total liabilities | $719.7M | $707.2M | $729.5M | $696.8M | $665.4M | $623.1M | $1.07B | $1.02B |
| Stockholders' equity | $4.77B | $4.73B | $4.57B | $4.40B | $4.30B | $4.09B | $4.18B | $4.07B |
| Total current assets | $2.22B | $2.20B | $2.13B | $1.92B | $1.73B | $1.71B | $2.18B | $2.06B |
| Total current liabilities | $479.3M | $482.5M | $498.5M | $466.0M | $424.7M | $384.7M | $855.9M | $818.1M |
| Cash & equivalents | $507.7M | $561.0M | $526.2M | — | — | — | $784.4M | — |
| Marketable securities (current) | $87.4M | $68.9M | $31.1M | $18.8M | — | — | $105.6M | $71.9M |
| Accounts receivable | $692.2M | $686.4M | $678.9M | $619.1M | $611.6M | $535.1M | $557.7M | $588.0M |
| Inventory | $810.9M | $772.6M | $759.3M | $771.5M | $772.1M | $663.6M | $659.2M | $717.7M |
| Marketable securities (non-current) | $245.4M | $169.4M | $71.8M | $16.7M | — | — | $66.1M | $12.3M |
| Property, plant & equipment | $533.5M | $557.1M | $564.5M | $577.8M | $587.5M | $556.5M | $561.9M | $567.8M |
| Goodwill | $1.44B | $1.44B | $1.44B | $1.43B | $1.43B | $1.43B | $1.43B | $1.43B |
| Intangible assets | $692.6M | $720.8M | $745.1M | $773.9M | $796.4M | $771.7M | $795.1M | $842.8M |
| Other non-current assets | $79.2M | $79.0M | $78.8M | $76.8M | $74.8M | $74.9M | $75.1M | $76.6M |
| Accounts payable | $106.9M | $103.7M | $98.9M | $87.2M | $87.1M | $73.1M | $75.1M | $57.5M |
| Accrued liabilities | $300.7M | $313.4M | $333.6M | $325.9M | $281.7M | $237.6M | $260.6M | $255.3M |
| Deferred revenue (current) | $28.0M | $26.3M | $27.7M | — | — | — | $22.1M | — |
| Other non-current liabilities | $19.0M | $20.6M | $21.3M | $25.1M | $22.1M | $25.5M | $21.5M | $23.0M |
| Common stock & paid-in capital | — | — | — | — | — | — | — | — |
| Retained earnings | $1.53B | $1.51B | $1.39B | $1.29B | $1.21B | $1.04B | $1.15B | $1.13B |
| Accumulated other comprehensive income (loss) | $11.2M | $14.4M | $15.3M | $10.9M | $10.2M | -$2.2M | -$6.9M | -$7.0M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $209.7M | $202.4M | $248.6M | $249.7M | $77.9M | $177.3M | $210.3M | $203.7M |
| Investing cash flow | -$129.0M | -$182.7M | -$111.4M | -$75.8M | -$299.1M | $131.4M | -$104.1M | -$15.0M |
| Financing cash flow | -$134.5M | $18.2M | $13.2M | -$32.0M | -$24.9M | -$635.4M | $59.7M | $19.6M |
| Free cash flow | $176.6M | $162.7M | $202.4M | $213.9M | $31.3M | $141.2M | $193.2M | $161.7M |
| Capital expenditures | $33.2M | $39.6M | $46.2M | $35.8M | $46.6M | $36.1M | $17.1M | $42.0M |
| Depreciation & amortization | $69.5M | $69.9M | $69.0M | $71.5M | $70.6M | $65.7M | $67.6M | $66.9M |
| Share-based compensation | $13.4M | $12.6M | $11.4M | $11.5M | $13.6M | $13.2M | $11.9M | $12.2M |
| Deferred income taxes | — | — | — | — | — | — | -$134.0M | — |
| Change in accounts receivable | $13.8M | $13.4M | $64.2M | $8.4M | $2.2M | -$22.6M | -$22.5M | -$23.7M |
| Change in inventory | $27.9M | $16.7M | $178.0K | $5.7M | $4.1M | $7.6M | $11.9M | -$4.9M |
| Change in accounts payable | $307.0K | $5.1M | $9.1M | $3.4M | -$3.2M | -$899.0K | $16.4M | -$10.3M |
| Purchases of investments | $107.6M | $146.4M | $105.8M | — | $0 | $1.8M | $113.5M | — |
| Sales/maturities of investments | — | — | $0 | $0 | $0 | $115.6M | $2.2M | $2.2M |
| Share repurchases | $136.1M | $0 | $45.0M | $40.0M | $25.0M | $190.5M | $1.0M | $0 |
| Debt repaid | — | — | — | — | — | — | — | — |
| Tax withholding on stock comp | $13.0K | $3.4M | $211.0K | -$255.0K | $660.0K | $2.3M | -$66.0K | $840.0K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $2.94B | $2.52B | $1.57B | $1.02B | $958.1M |
| Gross profit | — | — | $1.02B | $759.1M | $718.9M |
| Operating income | $479.8M | $166.0M | $133.1M | $228.0M | $172.0M |
| Net income | $537.9M | $103.0M | $122.9M | $190.2M | $149.2M |
| EPS (diluted) | $3.92 | $0.75 | $1.07 | $1.85 | $1.44 |
| EPS (basic) | $3.98 | $0.76 | $1.09 | $1.89 | $1.48 |
| Operating margin | $16 | $7 | $8 | $22 | $18 |
| Net margin | $18 | $4 | $8 | $19 | $16 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Sep '22 |
|---|---|---|---|---|---|
| Total assets | $5.30B | $5.25B | $5.09B | $2.08B | — |
| Total liabilities | $729.5M | $1.07B | $1.09B | $229.8M | — |
| Stockholders' equity | $4.57B | $4.18B | $4.00B | $1.85B | $1.76B |
| Total current assets | $2.13B | $2.18B | $1.92B | $983.3M | — |
| Total current liabilities | $498.5M | $855.9M | $392.3M | $159.2M | — |
| Cash & equivalents | $526.2M | $784.4M | — | — | — |
| Marketable securities (current) | $31.1M | $105.6M | $50.5M | $295.6M | — |
| Accounts receivable | $678.9M | $557.7M | $503.2M | $213.2M | — |
| Inventory | $759.3M | $659.2M | $848.1M | $299.0M | — |
| Marketable securities (non-current) | $71.8M | $66.1M | $75.4M | $495.9M | — |
| Property, plant & equipment | $564.5M | $561.9M | $586.9M | $243.7M | — |
| Goodwill | $1.44B | $1.43B | $1.43B | $197.5M | — |
| Intangible assets | $745.1M | $795.1M | $924.6M | $63.6M | — |
| Other non-current assets | $78.8M | $75.1M | $78.6M | $37.3M | — |
| Accounts payable | $98.9M | $75.1M | $56.7M | $36.1M | — |
| Accrued liabilities | $333.6M | $260.6M | $240.5M | $92.2M | — |
| Deferred revenue (current) | $27.7M | $22.1M | — | — | — |
| Other non-current liabilities | $21.3M | $21.5M | $24.6M | $10.3M | — |
| Common stock & paid-in capital | — | — | — | — | — |
| Retained earnings | $1.39B | $1.15B | $1.14B | $1.24B | — |
| Accumulated other comprehensive income (loss) | $15.3M | -$6.9M | -$10.2M | -$24.6M | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | $753.4M | $520.6M | $243.5M | $178.5M | $276.3M |
| Investing cash flow | -$355.0M | -$176.1M | $303.0M | -$110.4M | -$375.9M |
| Financing cash flow | -$679.2M | -$27.7M | -$231.8M | -$110.0M | $54.1M |
| Free cash flow | $588.8M | $405.2M | $165.2M | $104.4M | $219.4M |
| Capital expenditures | $164.7M | $115.4M | $78.3M | $74.0M | $56.9M |
| Depreciation & amortization | $276.8M | $253.4M | $145.5M | $68.3M | $69.9M |
| Share-based compensation | $49.8M | $54.2M | $52.7M | $32.8M | $30.6M |
| Deferred income taxes | — | -$134.0M | -$58.2M | -$22.3M | -$17.6M |
| Change in accounts receivable | $52.2M | $78.1M | $49.9M | $50.8M | $25.9M |
| Change in inventory | $17.6M | $29.9M | $70.3M | $61.7M | $12.0M |
| Change in accounts payable | $8.5M | $17.7M | -$14.2M | $14.4M | $3.7M |
| Purchases of investments | $107.5M | $113.5M | $100.6M | — | — |
| Sales/maturities of investments | $115.6M | $11.9M | $537.7M | $102.4M | $109.9M |
| Share repurchases | $300.5M | $85.8M | $225.6M | $144.5M | — |
| Debt repaid | — | — | — | — | — |
| Tax withholding on stock comp | $2.9M | $6.7M | $10.6M | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding GMED as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-01-02 to 2026-09-15
Recent transactions
- Insiders have net sold 80,000 shares over the last 182 days, across 0 purchases and 3 sales.
- Most recent: TOBIN JAMES R (Reporting person) — Option exercise of 15,000 shares on 2026-09-15.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)80,000 sh(3 txns)
Net Shares-80,000
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| TOBIN JAMES R | Reporting person | Option exercise | 2026-09-15 | 15,000 |
| ZARRILLI STEPHEN T | Reporting person | Option exercise | 2026-08-18 | 25,000 |
| Davidar David D | Reporting person | Gift | 2026-07-27 | 2,500 |
| RHOADS ANN D | Reporting person | Option exercise | 2026-06-04 | 25,000 |
| Huller Kelly | EVP, GC, Corporate Secretary | Option exercise | 2026-02-25 | 20,000 |
| Kline Kyle | Senior Vice President, CFO | Option exercise | 2026-01-08 | 3,594 |
| Norwalk Leslie V | Reporting person | Open market sale | 2026-01-08 | 2,000 |
| Paul David C | Executive Chairman | Option exercise | 2025-12-08 | 34,375 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-15 | TOBIN JAMES R | Reporting person | Option exercise | 15,000 | $53.75 |
| 2026-09-15 | TOBIN JAMES R | Reporting person | Option exercise | 15,000 | $63.68 |
| 2026-09-15 | TOBIN JAMES R | Reporting person | Open market sale | 30,000 | $74.58 |
| 2026-08-18 | ZARRILLI STEPHEN T | Reporting person | Option exercise | 25,000 | $53.27 |
| 2026-08-18 | ZARRILLI STEPHEN T | Reporting person | Open market sale | 25,000 | $87.04 |
| 2026-07-27 | Davidar David D | Reporting person | Gift | 2,500 | $0.00 |
| 2026-06-05 | Davidar David D | Reporting person | Option exercise | 25,000 | $26.27 |
| 2026-06-05 | Davidar David D | Reporting person | Open market sale | 25,000 | $80.76 |
| 2026-06-04 | RHOADS ANN D | Reporting person | Option exercise | 25,000 | $26.27 |
| 2026-02-25 | Huller Kelly | EVP, GC, Corporate Secretary | Option exercise | 20,000 | $43.58 |
| 2026-02-25 | Huller Kelly | EVP, GC, Corporate Secretary | Open market sale | 20,000 | $94.50 |
| 2026-02-12 | Huller Kelly | EVP, GC, Corporate Secretary | Option exercise | 10,000 | $45.64 |
| 2026-02-12 | Huller Kelly | EVP, GC, Corporate Secretary | Open market sale | 10,000 | $87.67 |
| 2026-01-08 | Kline Kyle | Senior Vice President, CFO | Option exercise | 3,594 | $51.87 |
| 2026-01-08 | Kline Kyle | Senior Vice President, CFO | Open market sale | 3,594 | $101.10 |
| 2026-01-08 | Norwalk Leslie V | Reporting person | Open market sale | 2,000 | $101.10 |
| 2025-12-12 | Norwalk Leslie V | Reporting person | Open market sale | 4,000 | $88.85 |
| 2025-12-08 | Paul David C | Executive Chairman | Option exercise | 34,375 | $25.52 |
| 2025-01-02 | Davidar David D | Reporting person | Gift | 6,100 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 07:51 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-16 | 4 | 2026-09-15 | View on SEC.gov → |
| 2026-08-19 | 4 | 2026-08-18 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-07-28 | 4 | 2026-07-27 | View on SEC.gov → |
| 2026-06-09 | 4 | 2026-06-05 | View on SEC.gov → |
| 2026-06-08 | 4 | 2026-06-04 | View on SEC.gov → |
| 2026-06-04 | 8-K | 2026-06-03 | View on SEC.gov → |
| 2026-05-07 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-07 | 8-K | 2026-05-07 | View on SEC.gov → |
| 2026-03-23 | 8-K | 2026-03-23 | View on SEC.gov → |
| 2026-02-27 | 4 | 2026-02-25 | View on SEC.gov → |
Recent news
Headlines about GMED (GLOBUS MEDICAL INC). Links open the publisher — we don’t host full articles.
-
Intuitive Surgical's Q3 Earnings Beat Estimates on Strong System Sales
Yahoo · 2026-10-21 -
ABT Stock Down Post Q3 Earnings Miss, Revenues Rise Y/Y, Margins Up
Yahoo · 2026-10-21 -
Stryker's Sonopet 3 Secures FDA Clearance to Improve Surgical Accuracy
Yahoo · 2026-10-21 -
A Look at Globus Medical Inc (GMED) After 4.4% Gain -- GF Value $97.21 vs Price $78.96
GuruFocus · 2026-10-20 -
Stifel keeps a USD 76.43 target for Globus Medical stock
AD HOC NEWS · 2026-10-20 -
Globus Medical (GMED) Unveils New Spine Platforms Following A Narrative Of Undervaluation
Simply Wall Street · 2026-10-17 -
Stifel keeps USD 76.43 target for Globus Medical stock - ad-hoc-news.de
ad-hoc-news.de · 2026-10-17 -
Globus Medical, Inc. (GMED) Stock Forecasts
Yahoo! Finance Canada · 2026-10-17
No headlines in this category right now — try “All”.